EUVIMEDEUVIMED entdecken
Open Access

A hematological and inflammatory marker-based model for prostate carcinoma diagnosis

Peiyi Guo, Garu A, Tao Chen, Yuanqing Guo, Yubo Tang, Jiangang Pan, Bin Wang, Rui Gong, Guangfu Chen, Sheng Huang

American Journal of Cancer Research · 2025 · 15 (6) · 2551-2563

DOI: 10.62347/tvfq4646 ↗

Kurz gefasst

Fachartikel in der Zeitschrift American Journal of Cancer Research, 2025. Verfasst von Peiyi Guo und 9 weiteren Autor:innen. Beteiligte Einrichtung: Centrum für Muskuloskeletale Chirurgie, Campus Virchow Klinikum, Charité - Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin a…. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 33 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Prostate carcinoma (PC) is the most frequently diagnosed malignancy and the third leading cause of cancer-related death among men in the United States, with over 160,000 new cases reported annually. While prostate-specific antigen (PSA) screening has advanced the early detection and management of PC, its diagnostic accuracy, particularly in distinguishing malignant from benign conditions, remains controversial. Therefore, this study aimed to improve the accuracy and efficiency of early PC diagnosis by constructing a diagnostic model based on hematological indicators. Emerging inflammatory markers such as the neutrophil-to-lymphocyte ratio (NLR), platelet-to-lymphocyte ratio (PLR), and C-reactive protein (CRP) were incorporated to supplement traditional PSA testing. This study employed a retrospective design and included 317 patients receiving prostate puncture at Foshan Fosun Chancheng Hospital of Guangdong Medical University between January 2019 and January 2022 as the research subjects. These patients were grouped into two categories: 126 diagnosed with PC and 191 diagnosed with benign prostatic hyperplasia, based on histopathological examination of the biopsy samples. Clinical and laboratory data were extracted from the electronic medical record system. Diagnostic markers for PC were screened by logistic regression and least absolute shrinkage and selection operator (LASSO) regression. The diagnostic performance of the model was evaluated using ROC and decision curve analysis. PSA, Neu, Mono, CRP, NLR, NAR, and CK-MB were identified as independent diagnostic indicators, effectively distinguishing PC from benign prostatic hyperplasia. The LASSO regression-based predictive model achieved an AUC of 0.850, significantly outperforming the traditional logistic regression model (AUC=0.792; P=0.042, Delong test), indicating superior diagnostic accuracy and model performance. In conclusion, the combination of traditional PSA testing and emerging inflammatory markers can significantly enhances early diagnostic accuracy for PC and the proposed model offers a promising approach for early detection and clinical decision-making.

Schlagwörter

Stichwörter der Autor:innen

Hematologyclinical significancediagnostic modelprostate carcinomarisk

Autor:innen und Institutionen

  • Centrum für Muskuloskeletale Chirurgie, Campus Virchow Klinikum, Charité - Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin Augustenburger Platz 1, 13353, Berli…
  • Department of Orthopaedic Surgery, Foshan Fosun Chancheng Hospital of Guangdong Medical University Foshan 528031, Guangdong, China.
  • Department of Orthopaedic Surgery, The Second Affiliated Hospital of Guangzhou Medical University Guangzhou 510260, Guangdong, China.
  • Department of Orthopaedic Surgery, The Fifth Affiliated Hospital of Sun Yat-Sen University Zhuhai 528406, Guangdong, China.
  • Department of Pharmacy, The First Affiliated Hospital of Sun Yat-Sen University Guangzhou 510080, Guangdong, China.
  • Department of Urology Surgery, The Second Affiliated Hospital of Guangzhou Medical University Guangzhou 510260, Guangdong, China.

Zitieren

APA

Guo, P., A, G., Chen, T., Guo, Y., Tang, Y., Pan, J., Wang, B., Gong, R., Chen, G., & Huang, S. (2025). A hematological and inflammatory marker-based model for prostate carcinoma diagnosis. American Journal of Cancer Research, 15(6), 2551-2563. https://doi.org/10.62347/tvfq4646

Vancouver

Guo P, A G, Chen T, Guo Y, Tang Y, Pan J, et al. A hematological and inflammatory marker-based model for prostate carcinoma diagnosis. American Journal of Cancer Research. 2025;15(6):2551-2563. doi:10.62347/tvfq4646

BibTeX
@article{Guo2025,
  author = {Guo, Peiyi and A, Garu and Chen, Tao and Guo, Yuanqing and Tang, Yubo and Pan, Jiangang and Wang, Bin and Gong, Rui and Chen, Guangfu and Huang, Sheng},
  title = {A hematological and inflammatory marker-based model for prostate carcinoma diagnosis},
  journal = {American Journal of Cancer Research},
  year = {2025},
  volume = {15},
  number = {6},
  pages = {2551--2563},
  doi = {10.62347/tvfq4646}
}
Kostenlos starten →